Tenax Therapeutics (TENX) Stock: Buy, Sell, or Hold?
TENX - Tenax Therapeutics, Inc.
$1.86
-0.09 (-4.62%)
âŧ
5d:
+4.49%
30d:
+8.14%
90d:
-82.67%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When TENX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TENX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TENX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: TENX is currently trading at $1.86, which is considered fair relative to its 30-day fair value range of $-0.54 to $8.33.
Technical Outlook: Technically, TENX is in a strong downtrend. Immediate support is located at $1.73, while resistance sits at $2.29. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: TENX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.56 (+575.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TENX is in a strong downtrend. Immediate support is located at $1.73, while resistance sits at $2.29. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: TENX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.56 (+575.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$-0.54 -
$8.33
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 575.0% below Wall St target ($12.56)
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$-0.54 -
$8.33
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.73
Resistance Level
$2.29
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.24
Wall Street Target
$12.56
(+575.0%)
Share & Embed Analysis
Last updated: September 12, 2026 12:51 AM ET
Data refreshes hourly during market hours. Next update: 1:51 AM
Data refreshes hourly during market hours. Next update: 1:51 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TENX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
